RENALYTIX PLC

Management Reports • Dec 9, 2025

National Storage Mechanism | Additional information

RNS Number : 8519K

Renalytix PLC

09 December 2025

Renalytix plc

("Renalytix" or the "Company")

Result of AGM

LONDON and NEW YORK, 9 December 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease,  announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

The results of the AGM are detailed below:

		For	% voted in favour	Against	% voted against	Withheld
Ordinary resolutions
1	Receive and adopt the UK 2025 Annual Report	196,930,280	99.7	587,105	0.3	20,878
2	Approve Directors' Remuneration Report	195,421,372	98.9	2,073,488	1.1	43,403
3	Re-appointment of Christopher Mills as a Director	178,267,303	90.3	19,130,050	9.7	140,910
4	Re-appointment of James McCullough as a Director	194,129,345	98.3	3,268,008	1.7	140,910
5	Re-appointment of Fergus Fleming as a Director	195,999,932	99.3	1,386,266	0.7	152,065
6	Re-appointment of Erik Lium as a Director	177,457,676	89.9	19,928,522	10.1	152,065
7	Re-appointment of Julian Baines as a Director	195,385,929	99.3	1,378,854	0.7	773,480
8	Re-appointment of Robert Naylor as a Director	196,012,978	99.3	1,373,220	0.7	152,065
9	Reappoint PKF Littlejohn LLP as Auditors	196,188,779	99.3	1,276,304	0.7	73,180
10	Authorise Board to determine auditors' remuneration	196,927,685	99.7	555,598	0.3	54,980
11	Authorise the Issue of Equity	195,214,647	98.9	2,147,594	1.1	176,022
Special resolutions
12	Authorise Issue of Equity without Pre-emptive Rights	193,317,050	97.9	4,042,090	2.1	179,123
13	Authorise Market Purchase of Ordinary Shares	195,114,033	98.8	2,381,796	1.2	18,678

For further information, please contact:

Renalytix plc		www.renalytix.com
James McCullough, CEO		Via Walbrook PR
SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)			Tel: +44 (0)20 3470 0470
Jeff Keating / David Hignell (Corporate Finance) Vadim Alexandre (Corporate Broking)
Oberon Capital (Joint Broker)		Tel: +44 (0)20 3179 5300
Mike Seabrook / Nick Lovering
Walbrook PR Limited	Tel: +44 (0)20 7933 8780 or [email protected]
Paul McManus / Alice Woodings		Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

About Renalytix (www.renalytix.com)

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.

Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting approximately 15 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.

The over 15,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).

KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix. For information about the kidneyintelX,dkd test, visit kidneyintelx.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBGBDDUUGDGUC